<!DOCTYPE html>
<html>
<head>
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <meta name="description" content="My name is Michael Bernauer, I'm a 4th year PharmD student at  the University of New Mexico College of Pharmacy. In addition to pharmacy, my interests include programming (R, Python, Julia, MySQL), machine learning, data analysis, health informatics, pharmacovigilance, and data mining.
">
  <meta name="keywords" content="bernauer, michael l bernauer, michael, UNM, pharmacy, informatics">
  <title>Michael L. Bernauer</title>
  <link rel="shortcut icon" type="image/x-icon" href="../img/portrait_crop.png"/>
  <!-- link type="text/css" rel="stylesheet" media="all" href="../../css/reset.css"/>-->
  <link type="text/css" rel="stylesheet" media="all" href="../../css/default.css"/>
  <link type="text/css" rel="stylesheet" media="all" href="../../css/syntax.css"/>
  <script type="text/javascript" src="../../js/smoothscroll.js">
  <script type="text/javascript" src="http://ajax.googleapis.com/ajax/libs/jquery/1.4.3/jquery.min.js"></script>
  <link href='http://fonts.googleapis.com/css?family=Cambo' rel='stylesheet' type='text/css'>

  <!-- Used to display interactive particle banner -->
  <!--
  <script language="javascript" src="/js/p5.js"></script>
  <script src="/banner/sketch.js"></script>
  -->
</head>

<body>
<div id="header">
  <div class="transparent">
    <div class="nav">
      <ul>
        <li><a href="http://mlbernauer.github.io/#home">Michael L. Bernauer</a></li>
        <li><a href="http://mlbernauer.github.io/#about">About</a></li>
        <li><a href="http://mlbernauer.github.io/#projects">Projects</a></li>
        <li><a href="http://mlbernauer.github.io/assets/2015_bernauer_curriculum_vitae.pdf">Curriculum Vitae</a></li>
        <li><a href="/pages/downloads">Downloads</a></li>
        <li><a href="/pages/slides">Slides</a></li>
        <li><a href="#contact">Contact</a></li>
      </ul>
    </div>
  </div>
</div>

<div class="page_container">
  <div class="content">
    <h1></h1>
    <div class="deets">
      <span class="date"></span>
    </div>
    <h1 id="acute-coronary-syndrome">Acute Coronary Syndrome</h1>

<p><em>Created by <a href="http://mlbernauer.com">Michael L. Bernauer</a> on 2016-01-03</em></p>

<h3 id="classification">Classification</h3>

<p><em>Acute coronary syndromes</em> include syndroms consistent with acute myocardia
which result from an imablance in myocardial oxygen demand and supply.</p>

<ul>
<li>ACS can be broken into two categories based on ECG changes

<ul>
<li>ST-segment-elevation:

<ul>
<li>STEMI</li>
</ul></li>
<li>Non-ST-segment-elevation:

<ul>
<li>Non-STEMI</li>
<li>Unstable Angina</li>
</ul></li>
</ul></li>
</ul>

<h3 id="pathophysiology">Pathophysiology</h3>

<ul>
<li>Endothelial dysfunction, inflammation and fatty streaks contribute to the formation of athersclerotic plaques.</li>
<li>Ninety percent of ACS patients experience ruptured, fissured, erosion of plaques.

<ul>
<li>Plaque rupture &rarr; collagen/tissue factor exposed &rarr; ADP and thromboxane A<sub>2</sub> released from platelets &rarr; more platelet activation &rarr; glycoprotein IIb/IIIa conformation change which facilitates fibrinogen cross-bridges &rarr; clotting.</li>
</ul></li>
<li>Blood exposed to thrombogenic lipid core (rich in tissue factor) results in simultaneous activation of extrinsic coagulation cascade resulting in fibrin clot (fibrin strands, cross-linked platelets, trapped RBCs)</li>
<li>MI &rarr; ventricular remodeling &rarr; left ventricular dilation &rarr; reduced pumping function &rarr; cardiac failure</li>
<li>MI complications:

<ul>
<li>Cardiogenic shock</li>
<li>HF</li>
<li>Valvular dysfunction</li>
<li>Arrhythmias</li>
<li>Pericarditis</li>
<li>Stroke secondary to left ventricular thrombus embolization</li>
<li>venous thromboembolism</li>
<li>LV free-wall rupture</li>
</ul></li>
</ul>

<h2 id="clinical-presentation">Clinical presentation</h2>

<ul>
<li>Midline anterior chest discomfort at rest</li>
<li>Sever new-onset angina or increasing angina lasting at least 20 minutes

<ul>
<li>May radiate to shoulder, down left arm, to back or jaw.</li>
</ul></li>
<li>Nausea, vomiting, diaphoresis and SOB are also common</li>
<li>ACS patients may have signs of acute HF or arrhythmias on physical exam</li>
</ul>

<h2 id="diagnosis">Diagnosis</h2>

<ul>
<li>Obtain 12-lead ECG within 10 minutes

<ul>
<li>MI findings include:

<ul>
<li>ST-segment-elevation, ST-segment-depression, inverted T-wave</li>
<li>Some MI patients have no ECG changes and thus biomarkers and other coronary artery disease (CAD) risk factors should be assessed.</li>
</ul></li>
</ul></li>
<li>Biomarkers are useful for confirming MI

<ul>
<li>MI confirmed by rise/fall of cardiac troponin

<ul>
<li>At least one reading &gt; 99 percentile of upper reference limit + one
of the following:

<ol>
<li>symptoms of ischemia</li>
<li>new significant ST-changes</li>
<li>pathological Q waves</li>
<li>imaging showing loss of myocardium or abnormal wall movement.</li>
</ol></li>
</ul></li>
<li>Obtain blood sample once in ED then 6-9 hours later</li>
</ul></li>
</ul>

<h3 id="treatment">Treatment</h3>

<h4 id="goals">Goals:</h4>

<ul>
<li>Immediate goals

<ol>
<li><strong>Restore blood flow</strong> to infarcted tissue</li>
<li><strong>Prevent death</strong> and complications</li>
<li><strong>Prevent reocclusion</strong></li>
<li><strong>Relieve ischemic chest discomfort</strong></li>
<li><strong>Restore to normal ST-segment, T-wave</strong></li>
</ol></li>
<li>Long term goals:

<ol>
<li><strong>Control risk factors</strong></li>
<li><strong>Prevent additional events</strong></li>
<li><strong>Improve quality of life</strong></li>
</ol></li>
</ul>

<h4 id="general-approach">General approach</h4>

<ol>
<li><strong>Oxygen</strong> if saturation &lt; 90%</li>
<li><strong>Stool softener</strong> to prevent Valsalva maneuver</li>
<li><strong>Pain relief</strong> and <strong>bedrest</strong></li>
<li><strong>Obtain baseline labs</strong>: K, Mg, glucose, creatinine, CBC, coagulation tests, and fasting
lipds

<ul>
<li>Lipids should be obtained with 24 hours of hopitalization; cholesterol is
acute phase reactant and may be low after</li>
</ul></li>
</ol>

<ul>
<li><strong>STEMI</strong> patients should undergo immediate <strong>reperfusion and adjunct pharmacotherapy</strong></li>
</ul>

<h4 id="nonpharmacologic">Nonpharmacologic</h4>

<ul>
<li><strong>STEMI:</strong>

<ul>
<li>If &lt; 12 hours from symptom onset <strong>start PCI within 90 minutes of first medical contact</strong></li>
</ul></li>
<li><strong>NSTEM ACS:</strong>

<ul>
<li><strong>Coronary angiography</strong> + (<strong>PCI</strong> OR <strong>CABG</strong>)</li>
</ul></li>
</ul>

<h4 id="stemi-pharmacothearpy">STEMI pharmacothearpy</h4>

<ul>
<li>All STEMI patients should be receive the following in the ED

<ol>
<li><strong>Oxygen</strong> (if saturation is low)</li>
<li>*<em>Sublinqual NTG *</em></li>
<li><strong>ASA</strong></li>
<li><strong>P2Y<sub>12</sub> inhibitors</strong> (clopidogrel, prasugrel, ticagrelor)</li>
<li>Anticoagulation with <strong>bivaliruden, UFH, enoxaparin</strong></li>
</ol></li>
<li><strong>If undergoing PCI</strong> GP IIb/IIIa inhibitors (<strong>abiximab, eptifibatide, tirofiban</strong>) + <strong>UFH</strong></li>
<li><strong>IV NTG</strong> and <strong>IV &beta;-blockers</strong> should be given to select patients</li>
<li><strong>Oral &beta; blockers</strong> should be given on first day to patients without cardiogenic shock</li>
<li><strong>Morphine</strong> should be given if refractory angina to provide analgesic and vasodilatin (lower preload)</li>
<li>Start <strong>ACE</strong> inhibitors within 24 hours in patients with <strong>anterior wall MI</strong> or <strong>LVEF &le; 40%</strong> and no contraindications</li>
</ul>

<h5 id="fibrinolytic-thearpy">Fibrinolytic thearpy</h5>

<ul>
<li>Given to <strong>STEMI</strong> + <strong>&le; 12 hours FMC</strong> + <strong>unable to perform PCI with 120 min of FMC</strong>

<ul>
<li>If &gt; 12 hours, only use if ongoing ischemia is present</li>
</ul></li>
<li>Do not need biomarker results to initiate</li>
<li><strong>Contraindications (use PCI instead):</strong>

<ol>
<li>Hx of hemorrhagic Stroke</li>
<li>Ischemic stroke within 12 months</li>
<li>Internal bleeding</li>
<li>Intracranial neoplasm</li>
<li>Cerebrovascular lesion</li>
<li>Aortic dissection</li>
<li>Head/facial trauma within 3 months</li>
</ol></li>
<li>Fibrin specific agent preferred (<strong>alteplase, reteplase, tenecteplase</strong>) over nonspecific agent (streptokinase)</li>
<li>Administer fibrinolytics ASAP (ideally within 30 min of ED)</li>
<li><strong>Alteplase</strong>: 15 mg IV bolus + 0.75mg/kg (max 50mg) over 30 min &rarr; 0.5 mg/kg (max 35 mg) over 60 min (max 100 mg)</li>
<li><strong>Reteplase</strong>: 10U IV over 2 min &rarr; 10U IV over 2 min 30 minutes later</li>
<li><strong>Tenecteplase</strong>: Single IV bolus given over 5 seconds

<ul>
<li>&lt; 60 kg: 30 mg</li>
<li>60-69.9 kg: 35 mg</li>
<li>70-79.9 kg: 40 mg</li>
<li>80-89.9 kg: 45 mg</li>
<li>&gt; 90 kg: 50 mg</li>
</ul></li>
<li><strong>Streptokinase</strong>: 1.5 million U in 50ml NS (or D5W) IV over 60 minutes</li>
<li><strong>Side Effects:</strong>

<ul>
<li><strong>Intracranial hemorrhage</strong> (ICH) and <strong>major bleeding</strong>

<ul>
<li>ICH risk: Alteplase, reteplase, tenecteplase &gt; streptokinase</li>
<li>Systemic bleeding: streptokinase &gt; alteplase, reteplase, tenecteplase</li>
</ul></li>
</ul></li>
</ul>

<h5 id="aspirin">Aspirin</h5>

<ul>
<li>All patients get ASA <strong>within &pm; 24 hours of hospital</strong>

<ul>
<li>Additional mortality benefit in STE ACS when given with fibrinolytics</li>
</ul></li>
<li>160-325mg of <strong>non-enteric coated</strong> should be given a symptom onset or immediately at hospital</li>
<li>325mg if getting PCI and ASA note previously taken</li>
<li>75-162mg maintenance dose should be taken indefinately</li>
<li>Low dose (81 mg) recommended with P2Y<sub>12</sub> inhibitors after PCI</li>
<li>DC all other NSAIDS and COX_2 inhibitors due to increased mortality</li>
</ul>

<h5 id="p2y12-inhibitors">P2Y<sub>12</sub> inhibitors</h5>

<ul>
<li><strong>clopidogrel</strong>, <strong>prasugrel</strong>, <strong>ticagrelor</strong> block the platelet P2Y<sub>12</sub> ADP receptor
preventing binding of ADP and expression of GP IIb/IIIa receptors reducing platelet aggregation.</li>
<li><strong>P2Y<sub>12</sub></strong> in addition to <strong>ASA</strong> is recommended in all STEMI cases. <strong>P2Y<sub>12</sub></strong> + <strong>ASA</strong> in patients undergoing PCI to prevent stent thrombosis and CV events</li>
<li><strong>P2Y<sub>12</sub></strong> inhibitors should be given for at least 12 months following PCI (bare metal or drug eluting stents)</li>
<li>Withold <strong>clopidogrel</strong> and <strong>ticagrelor</strong> for 5 days prior to CABG and <strong>prasugrel</strong> for 7 days to reduce post-op bleeding</li>
<li><strong>Clopidogrel</strong>:

<ul>
<li>300 mg loading dose + 75 mg daily in patients receiving fibrinolytics</li>
<li>No loading dose if &gt; 75 years old</li>
<li>600 mg loading dose prior to PCI (300 mg if &lt; 24 hours of fibrinolytics)</li>
</ul></li>
<li><strong>Prasugrel</strong>: 60 mg LD + 10 mg daily for patients &ge; 60 kg.</li>
<li><strong>Ticagrelor</strong>: 180 mg LD in patients undergoing PCI + 90 mg BID</li>
<li><p><strong>Side effects</strong>:</p>

<ul>
<li>Nausea, vomiting, diarrhea</li>
<li>Rare thrombotic thrombocytopenic purpura (TTP) with clopidogrel</li>
</ul></li>
<li><p><strong>STEMI + fibrinolytics</strong>: Clopidogrel 300 mg LD + 75 mg daily x 28 days reduces mortality and risk of reinfarction without increased bleeding risk</p>

<ul>
<li>No LD if patient &ge; 75 years old</li>
</ul></li>
<li><p><strong>STEMI w/o reperfusion therapy</strong>: <strong>Clopidogrel</strong> + <strong>ASA</strong> x 14 days (up to 1 year)</p></li>
</ul>

<h5 id="gp-iib-iiia-receptor-inhibitors">GP IIb/IIIa receptor inhibitors</h5>

  </div>
</div>
<div>
  <!--CONTACT-->
<div id="contact">
  <div class="beginning">
    <h2>contact</h2>
  </div>
  <div class="wrap-one">
    <div class="social">
      <p class= "about">If you want to get in touch, email is probably best. But you have options.</p>
      <a href="mailto:mlbernauer@gmail.com" class="mailicon" title="mail"></a>
      <a href="http://twitter.com/mlbernauer" class="twittericon" title="twitter"></a>
      <a href="http://www.facebook.com/mbernauer" class="facebookicon" title="facebook"></a>
      <a href="https://github.com/mlbernauer" class="githubicon" title="github"></a>
      <a href="https://www.flickr.com/photos/mlbernauer/" class="flickricon" title="flickr"></a>
    </div>
  </div>
</div>

  <!--FOOTER-->
<div id="footer"></div>

</div>
</body>
</html>
